FY16 Results Presentation
FY16 Results Presentation
Sydney, Aug 24, 2016 AEST (ABN Newswire) - Regeneus Ltd (ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.

FY16 Financial Results Overview

- Licence fee revenues up 35% to $1.2m (FY15: $0.9m)

- R&D tax incentive of $2.7m claimed (FY15: $3.4m)

- Expenditure levels reduced in all categories a key benefit of the strategic changes taken throughout FY15

- Loss from ordinary activities reduced by 45% to $3.6 m (FY15: $6.6m)

Operating Cash Burn

- Quarterly cash burn down 37% to $1.48m per quarter (FY15: $2.35m per quarter) - better than stated target of $1.7m

- Net cash used in operating activities of $2.25m (including R&D tax incentive) (FY15: $5.92m)

- $2m R&D tax funding facility in place

- R&D tax incentive of $2.7m expected to be received mid September '16

Progenza FY16 Achievements

STEP Trial Update

- Commenced and completed recruitment for Progenza Phase 1 Study for osteoarthritis (STEP Trial)

- Positive safety review for both cohorts

- 12 month follow up on participants

Collaboration and licensing

- Progressed licensing discussions for manufacturing, clinical development and commercialisation in Japan

Product development and scale-up

- Collaboration with CSIRO on manufacture scale up-technologies

- Improvements to cell growth media to enhance yield

- Developed potency and identity assays

RGSH4K - Human Cancer Vaccine FY16 Achievements

- Established tumour bank - receiving patient samples to support vaccine manufacture

- First patient dosed safely Nov '15 - ACTIVATE trial open for enrollment

- Patients dosed safely in all 3 cohorts

- Assess emerging study data to:

-- investigate vaccine safety, and

-- identify a biologically active dose for further studies

- Exploring partnering for combination with check point inhibitors

CryoShot FY16 Achievements

- Commenced recruitment for 80 dog prepivotal trial at U.Penn to assess CryoShot for canine osteoarthritis more than 30% recruited

- Entered into agreement with top animal health pharma to partner development and commercialisation of CryoShot

- Positive clinical results for using CryoShot on early orthopaedic development disease in yearling thoroughbreds

- Commenced study in assessing CryoShot for strengthening equine tendons

Kvax - Canine Cancer Vaccine FY16 Achievements

- Completed clinical trial assessing Kvax for canine osteosarcoma as standalone treatment with Dr Bergman of VCA Hospital Inc., largest US vet services group

-- data readout from osteosarcoma trial in Oct '16

- Commenced clinical trial for Kvax in combination with chemotherapy for canine lymphoma with SASH

To view the full presentation, please visit:

About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.



Sandra McIntosh
Company Secretary and Investor Relations
T: +61-2-9499-8010
E: investors@regeneus.com.au
W: www.regeneus.com.au

Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 11) (Last 30 Days: 32) (Since Published: 2797) 

Regeneus Ltd NEWS: RECENT VISITS (5526)

Research Report

Social Media